Document is current
Any future updates will be listed below
-
Authors
Lorch, A.
Grimm, M.-O.
Weiss, C.
Bruns, C.
- License Information
-
More Information
Article History
Accepted: 13 July 2022
First Online: 22 August 2022
Interessenkonflikt
: A. Lorch macht folgende Angaben: Advisory Board/Honoraria: MSD, Merck, Pfizer, BMS, Novartis, Ipsen, Janssen, Roche, Astra Zeneca, Astellas, Bayer, Sanofi. Travel support: Ipsen. PI and Sub PI in several phase I, II and II trials in genitourinary oncology. M.-O. Grimm, C. Weiss und C. Bruns geben an, dass kein Interessenkonflikt besteht.
Free to read: This content has been made available to all.
